Johnson & Johnson and AstraZeneca, in collaboration with Oxford University, are studying changes to their new coronavirus vaccines to reduce or eliminate the risk of thrombosis, TASS reported, citing an article in the Wall Street Journal.
The study involved scientists from Europe, the United States and Canada, and their work “inspires hope that early next year they will be able to determine the causes of blood clots after immunization and make appropriate adjustments to the drugs.”
The study is still in its infancy, and at this stage it is unclear whether the vaccines can be modified, according to BTA.
The newspaper’s publication says that these manufacturers are currently selling their vaccines at a price equal to their cost, but may raise prices for developed countries after the end of the pandemic.
Addressing blood clots would increase public confidence in vaccines. Prior to publication, the researchers noted that the factors that lead to a rare type of thrombosis as a side effect of vaccines need to be clarified.